Semaglutide acts on GLP-1 receptors in the brain, the same pathway your body uses to signal fullness
Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA (2005) -Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis
Sinai Hospital and the University of Toronto in Toronto, Canada, is being recognized for having made seminal contributions to our understanding of the physiology and pharmacology of glucagon-like peptides (GLPs) and their use for the benefit of patients. His discoveries of GLP-1, GLP-2, and dipeptidyl peptidase-4 (DPP-4) activity have enabled the development of multiple new innovative classes of medications for the treatment of diabetes, obesity, and obesity-associated comorbidities
(PubMed) Dingchao H, Zhiduan Q, Liye H, Xiaodong F